Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.66 |
| ▸ | FNTB | P49356 | 1/20 | 0.66 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.56 |
| ▸ | RRM1 | P23921 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.53 |
| ▸ | NAAA | Q02083 | 2/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766649 | 0.92 | GNAI3 (0.60) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL8767404 | 0.92 | GNAI3 (0.60) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL8767020 | 0.92 | GNAI3 (0.60) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL1258601 | 0.89 | GNAI3 (0.56) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL20503323 | 0.87 | FNTA (0.68) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL5821091 | 0.85 | FNTA (0.56) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL24042511 | 0.82 | GLP1R (0.51) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL7865417 | 0.82 | PLA2G2A (0.55) | FNTAFNTBGPR84FFAR1 | |
| SCHEMBL10796126 | 0.81 | CNR1 (0.50) | FNTAFNTBGNAI3GNAO1GNAI1 | |
| SCHEMBL2482508 | 0.81 | GNAI3 (0.60) | FNTAFNTBGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131021-A1 | LIPID NANOPARTICLE-BASED DRUG DELIVERY SYSTEM USING RECOMBINANT PROTAMINE AND METHOD FOR PREPARING SAME | MOOGENE MEDI CO., LTD. (KR) | 2026-05-14 | — | — | US | claimed |
| EP-4566594-A1 | LIPID NANOPARTICLES COMPRISING LONG-CHAIN CERAMIDE AND COMPOSITION FOR CELL DEATH COMPRISING SAME | Croda Korea Limited (KR) | 2025-06-11 | — | — | EP | claimed |
| CN-119654140-A | Lipid nanoparticles comprising long chain ceramides and compositions for apoptosis comprising the same | 禾大韩国有限公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2025005632-A1 | LIPID NANOPARTICLE-BASED DRUG DELIVERY SYSTEM USING IONIZABLE PEPTIDE, AND METHOD FOR PREPARING SAME | 주식회사 무진메디 | 2025-01-02 | — | — | WO | claimed |
| WO-2024210692-A1 | HIGHLY WATER-DISPERSIBLE COMPOSITION HAVING HIGH CERAMIDE CONTENT | 주식회사 무진메디 | 2024-10-10 | — | — | WO | claimed |
| WO-2024029981-A1 | LIPID NANOPARTICLES COMPRISING LONG-CHAIN CERAMIDE AND COMPOSITION FOR CELL DEATH COMPRISING SAME | 주식회사 무진메디 | 2024-02-08 | — | — | WO | claimed |
| WO-2023204384-A1 | LIPID NANOPARTICLE-BASED DRUG DELIVERY SYSTEM USING RECOMBINANT PROTAMINE AND METHOD FOR PREPARING SAME | 주식회사 무진메디 | 2023-10-26 | — | — | WO | claimed |
| US-20170056555-A1 | LIPOSOME FOR DELIVERING EXTRACELLULAR MATRIX | Sogang University Research Foundation (KR) | 2017-03-02 | — | — | US | claimed |
| US-9359196-B2 | Antiproliferative compositions comprising curcumin analogs and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-06-07 | — | — | US | claimed |
| US-9173839-B2 | Anionic lipids and lipid nano-structures and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-11-03 | — | — | US | claimed |
| US-20130243688-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | UNIV OKLAHOMA (US) | 2013-09-19 | — | — | US | claimed |
| US-8420118-B2 | Anionic lipids and lipid nano-structures and methods of producing and using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2013-04-16 | — | — | US | claimed |
| US-20120288555-A1 | ANTIPROLIFERATIVE COMPOSITIONS COMPRISING CURCUMIN ANALOGS AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2012-11-15 | — | — | US | claimed |
| WO-2011031849-A2 | ANIONIC LIPIDS AND LIPID NANOSTRUCTURES AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2011-03-17 | — | — | WO | claimed |
| US-20110059157-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-03-10 | — | — | US | claimed |
| US-20260131021-A1 | LIPID NANOPARTICLE-BASED DRUG DELIVERY SYSTEM USING RECOMBINANT PROTAMINE AND METHOD FOR PREPARING SAME | MOOGENE MEDI CO., LTD. (KR) | 2026-05-14 | — | — | US | disclosed |
| EP-4566594-A1 | LIPID NANOPARTICLES COMPRISING LONG-CHAIN CERAMIDE AND COMPOSITION FOR CELL DEATH COMPRISING SAME | Croda Korea Limited (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-20120288555-A1 | ANTIPROLIFERATIVE COMPOSITIONS COMPRISING CURCUMIN ANALOGS AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2012-11-15 | — | — | US | disclosed |
| WO-2011031849-A2 | ANIONIC LIPIDS AND LIPID NANOSTRUCTURES AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059157-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288555-A1 | ANTIPROLIFERATIVE COMPOSITIONS COMPRISING CURCUMIN ANALOGS AND METHODS OF PRODUCING AND USING SAME | MCL1, LITAF, CTSA | FNTA 1136/4885FNTB 2009/4885GNAI3 2829/4885 |
| US-20130243688-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | SGMS2, SGMS1, PHOSPHO1 | FNTA 141/4885FNTB 398/4885GNAI3 2416/4885 |
| US-20260131021-A1 | LIPID NANOPARTICLE-BASED DRUG DELIVERY SYSTEM USING RECOMBINANT PROTAMINE AND METHOD FOR PREPARING SAME | PTDSS1, PLTP, PLIN3 | FNTA 2447/4885FNTB 3258/4885GNAI3 3902/4885 |
| US-20110059157-A1 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME | SGMS2, SGMS1, PHOSPHO1 | FNTA 141/4885FNTB 398/4885GNAI3 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.